Navigation Links
ViroPharma Announces First Quarter 2013 Financial Results
Date:5/1/2013

ntial effect of C1-INH in Refractory Paroxysmal Nocturnal Hemoglobinuria (PNH). ViroPharma plans to continue to conduct both clinical and non-clinical studies to evaluate additional therapeutic uses for its C1 INH product in the future.
  • Maribavir for cytomegalovirus – We are currently enrolling patients into a Phase 2 program to evaluate maribavir for the treatment of CMV infections in transplant recipients.  The program consists of two independent Phase 2 clinical studies that include subjects who have asymptomatic CMV in one trial, and those who have failed therapy with other anti-CMV agents in another trial.  Additional data from these ongoing studies will be provided during today's conference call.
  • VP-20629 for Friedreich's Ataxia (FA) – We expect to initiate a single and repeat dose phase 1 study in patients in 2013.
  • Oral Budesonide for eosinophilic esophagitis (EOE) – We currently have an exclusive option agreement to acquire Meritage Pharma, Incorporated based on predefined terms pending data outcomes from a Phase 2 study and concurrence with the U.S. FDA on an acceptable clinical endpoint for the Phase 3 program.  The Phase 2 study is currently enrolling with data expected in 2014.
  • 2013 Guidance ViroPharma is providing guidance for the year 2013 as a convenience to investors. The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties. For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

    For the year 2013, ViroPharma is providing the following update: 

  • Worldwide net product sales are expected to be $440 to $465 million;  
  • Net North American Cinryze sales are expected to be $390 to $400 million; and
  • Research and development (R&D) and selling, general
    '/>"/>

  • SOURCE ViroPharma Incorporated
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. ViroPharma to Participate in Two December Healthcare Investor Conferences
    2. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
    3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    4. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
    6. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
    7. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
    8. WuXi PharmaTech Announces Third-Quarter 2011 Results
    9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
    10. Spherix Announces Third Quarter Financial Results
    11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... -- Bionomics Limited (ASX:BNO, ADR:BMICY) is to present important ... patients with metastatic renal cancer at the ASCO Genitourinary ... The data will be presented by Dr. Sumanta ... Center in California in his ... Ferritin and IL-8 as two baseline biomarkers that correlate ...
    (Date:2/27/2015)... Brighton, Illinois (PRWEB) February 27, 2015 ... Matt Sims, General Manager of State Line Farms, received ... Award recognizes a producer, under the age of 35, ... , "It is an honor to win the Tomorrow's ... to discovering who won the Top Producer Award and ...
    (Date:2/27/2015)... BERKELEY, Calif. , Feb. 27, 2015  Steep ... in the US and internationally, intends to open a ... Albuquerque, New Mexico , bringing advanced scientific ... of cannabis. Steep Hill is currently the ... Health to conduct potency and contaminant testing in order ...
    (Date:2/26/2015)... NEW YORK , Feb. 26, 2015 ... commenced Factual Stock Report coverage on MabVax Therapeutics ... Inc. (MBVX) is a clinical stage biotechnology company focused ... address unmet medical needs in the treatment of cancer. ... products based on the protective immune responses generated by ...
    Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5
    ... In this month,s special issue of Physics World, which examines ... Kinsler of Imperial College London describe a new type of ... events. Using the ultimate bank heist as an example, ... use an "event cloak" to steal money from a safe, ...
    ... looked like when it was a baby. They know what ... it looked in its youth. Thanks to technological advances, however, ... picture of how the cosmos developed into the kind of ... They plan to gather these never-before-obtained insights with a ...
    ... Dendreon Corporation (Nasdaq: DNDN ) today ... on-label use of PROVENGE® (sipuleucel-T), the first autologous ... minimally symptomatic metastatic castrate resistant (hormone refractory) prostate ... U.S. Food and Drug Administration (FDA) approved the ...
    Cached Biology Technology:Why 'event cloaks' could be the key to the ultimate bank heist 2Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 2Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 3Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 4Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 2Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 3Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 4
    (Date:2/5/2015)... VIEW, Calif. , Feb. 3, 2015 /PRNewswire/ ... printer technology, demand from industries such as consumer ... global market for surface mount technology (SMT) screen ... equipment to automatic control will push the adoption ... dispensers will remain steady as glue dispensers are ...
    (Date:1/22/2015)... DETROIT , Jan. 13, 2015 Technology Showcase, Hall ... iris-based identity authentication solutions, today announced it will showcase its ... and developed by the Department of Energy,s Oak Ridge ... International Auto Show . EyeLock,s iris identity authentication technology is ...
    (Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
    Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
    ... CHAMPAIGN, lll. Blood clotting is a complicated business, ... to injury. In a new study, researchers report that they ... interaction that is vital to blood clotting. This interaction ... baffled scientists for decades. The study appears ...
    ... Research from North Carolina State University shows that ... good in landfills, because they are releasing a powerful ... such as disposable cups and utensils, are broken down ... Dr. Morton Barlaz, co-author of a paper describing the ...
    ... lightweight web service interface for accessing massive amounts ... and private domains has been developed by researchers ... powerful RIKEN Scientists, Networking System (SciNetS), the service ... to millions of data records and their network ...
    Cached Biology News:Team solves decades-old molecular mystery linked to blood clotting 2Team solves decades-old molecular mystery linked to blood clotting 3Study: Biodegradable products may be bad for the environment 2Web interface defines new paradigm for life science data-sharing 2
    Request Info...
    ... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
    Request Info...
    Request Info...
    Biology Products: